NOBLADS Profile • Severe LGIB Predictor
Composite Criteria
Select the presence of each admission risk factor to visualize the clinical severity index.
Guidelines & Evidence
Verified
Last Review: 2026-07-17
When to Use
When to Use
Prognostic stratification of patients with acute Lower Gastrointestinal Bleeding (LGIB)
To predict the need for clinical intervention (transfusion, endoscopy, or IR embolization)
Complementary tool to the Oakland score for identifying high-risk hospital admissions
Scoring Philosophy
NOBLADS is an acronym for the 7 variables used to quantify the risk of a severe bleeding event.
How it Works
The NOBLADS Components (0–1 pts each)
N: NSAID use (current).
O: Outpatient status (onset of bleeding while outside the hospital).
B: Blood pressure (SBP < 100 mmHg).
L: Low haemoglobin (< 10 g/dL).
A: Aspirin use (current).
D: Diabetes Mellitus (history).
S: Severe comorbidity (Renal/Hepatic/Heart failure).
Risk of Severe Bleeding
| Score 0 | 매우 Low Risk (Stable) |
| Score 1–2 | Low Risk |
| Score ≥ 3 | High Risk for transfusion and intervention |
Clinical Pearls
NOBLADS vs. Oakland
The Oakland score is the current "gold standard" for identifying patients safe for ED discharge. NOBLADS is more oriented toward predicting the "sick" patient who will need active management. It is particularly useful in Asia and Europe, where it was originally validated.
The "NSAID and Aspirin" weight
Unlike the GBS score for upper GI bleeding, NOBLADS heavily weights anti-inflammatory and anti-platelet use, acknowledging their critical role in the pathogenesis of diverticular bleeds and angiodysplasia erosion.
Clinical Pearls
A NOBLADS score of 0 has a very high negative predictive value for any clinical intervention
Severe comorbidities (S) significantly impair the patient's ability to compensate for rapid volume loss
Diabetes (D) is included due to its correlation with vasculopathy and potentially impaired visceral wound healing
Next Steps
Triage Recommendation
01
Score ≥ 3: Hospitalize; Type and Cross; Prioritize for Colonoscopy (or CTA if hemodynamically unstable).
02
Score 0–1: Evaluate using Oakland Score for potential outpatient management.
The Evidence
The Foundational Score
Development and validation of a risk scoring system for severe acute lower gastrointestinal bleeding.
Aoki T et al. • Clinical Gastroenterology and Hepatology. 2016;14(11):1562-1570. The primary derivation and validation study.
View Source• . ;
Origins & History
The Aoki Group
Developed by Tomonori Aoki and colleagues in Tokyo, Japan. Their goal was to move beyond "clinical intuition" and provide ED physicians with a structured evidence-based checklist for the increasingly common presentation of acute hematochezia.
Last Comprehensive Review: 2026-07-17